Literature DB >> 3196365

Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis.

D J Bjorkman1, E H Hammond, R G Lee, D O Clegg, K G Tolman.   

Abstract

Twenty-six patients receiving long-term oral methotrexate (MTX) therapy for rheumatoid arthritis (24 patients) or psoriasis (2 patients) were prospectively evaluated for alterations in liver morphology by light microscopy, electron microscopy, and immunofluorescence microscopy. Although only 4 MTX-treated patients had light microscopic evidence of mild fibrosis, all had evidence of collagen deposition in the space of Disse near Ito cells and changes in hepatocyte lysosomes on electron microscopy. These findings were absent from control livers. Fibrinogen, fibronectin, and type IV collagen were identified by immunofluorescence in both MTX-treated patients and controls. We conclude that long-term MTX therapy for rheumatoid arthritis is associated with alterations in hepatic ultrastructure, including collagen deposition in the space of Disse and changes in hepatocyte lysosomes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3196365     DOI: 10.1002/art.1780311202

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

Review 1.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 2.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis.

Authors:  Joseph Mathew; May Y Leong; Nick Morley; Alastair D Burt
Journal:  BMC Dermatol       Date:  2005-11-29

4.  Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis.

Authors:  Lindsey Tilling; Sue Townsend; Joel David
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes.

Authors:  Emilie Quintin; Jean-Yves Scoazec; Hubert Marotte; Pierre Miossec
Journal:  Arthritis Res Ther       Date:  2010-07-16       Impact factor: 5.156

6.  Two methods of assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis.

Authors:  P D Hall; M J Ahern; L R Jarvis; P Stoll; M A Jenner; H Harley
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

Review 7.  Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?

Authors:  E H Giannini; J T Cassidy
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

8.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 9.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

10.  Action of methotrexate on cytochrome P-450 monooxygenases in rats. Study performed with [13C]-aminopyrine micro breath test.

Authors:  J Guitton; G Souillet; J L Rivière; F Gerard; R Guilluy; J L Brazier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.